ArticleCureus2024
Recurrent Malignant Sweat Gland Tumor.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Case report: High-grade hidradenocarcinoma of the chest wall with insights fromFrontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant sweat gland tumors are very rare. Hidradenocarcinoma is an uncommon malignancy arising from the intradermal ductal epithelium of eccrine sweat glands, usually in the sun-exposed parts of the body. It usually arises de novo but may develop from a benign hidradenoma. The diagnosis of hidradenocarcinoma is clinically challenging as it presents with varied consistency and clinically mimics other skin lesions such as chronic sebaceous cysts or epidermoid cysts. Hidradenocarcinoma is a highly aggressive tumor with a tendency for regional and distant spread. It is difficult to treat hidradenocarcinoma as it has high rates of morbidity and mortality and a very high incidence of recurrence. Here, we report a rare case of a 45-year-old woman who presented with a recurrent lump over the left arm diagnosed as primary hidradenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.